← Leaderboards
Albert B Deisseroth
University Of Texas Md Anderson Can Ctr
$3,595,581
Attributed
$3,595,581
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $636.5K · FY2005–09$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$3,595,581 · 4
By mechanism
P01$2,902,895 · 3
R21$692,686 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Richard E. Champlin$5,988,814
- Konstantin V Sokolov$9,178,408
- Ralph Bernard Arlinghaus$3,580,180
- Francisco J Esteva$1,358,184
- Michael J Siciliano$1,505,448
Others in their field
Top investigators on “Human Tissue”
- David Heimbrook · Leidos Biomedical Research, Inc.$294,443,261
- Lawrence Corey · Fred Hutchinson Cancer Center$212,638,156
- Larry Arthur$131,303,476
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$114,079,276
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
Research focus
Human TissueApoptosisChimeric ProteinsCell ProliferationMelanomaImmunoglobulin GNeoplasm /Cancer ChemotherapyMolecular OncologyThromboplastinDrug ResistanceImmunoconjugatesBlood CoagulationLaboratory MouseBlood VesselsBlood Coagulation Factor ViiBlood CirculationAnimal TestingAdenovirus VectorCell LineAffinityBinding (Molecular Function)Cell CycleCellsChemotherapy
Grant awards (12)
ICON TARGETING OF TUMOR VASCULATURE AND TUMOR CELLS$636,541
P01 · FY2009 · CA · contact PI
ICON TARGETING OF TUMOR VASCULATURE AND TUMOR CELLS$622,231
P01 · FY2008 · CA · contact PI
ICON TARGETING OF TUMOR VASCULATURE AND TUMOR CELLS$616,916
P01 · FY2007 · CA · contact PI
ICON TARGETING OF TUMOR VASCULATURE AND TUMOR CELLS$397,856
P01 · FY2006 · CA · contact PI
ICON TARGETING OF TUMOR VASCULATURE AND TUMOR CELLS$386,804
P01 · FY2005 · CA
Tumor Neovasculature Vector Targeting$335,519
R21 · FY2003 · CA
Tumor Neovasculature Vector Targeting$357,167
R21 · FY2002 · CA
MOLECULAR SENSITIZATION OF P210BCR-ABL POSTIVIE CELLS TO THERAPY--CML$0
P01 · FY2002 · CA
MOLECULAR DETERMINANTS OF CHEMOTHERAPY RESISTANCE$0
P01 · FY2001 · CA
MOLECULAR SENSITIZATION OF P210BCR-ABL POSTIVIE CELLS TO THERAPY--CML$0
P01 · FY2001 · CA
MOLECULAR DETERMINANTS OF CHEMOTHERAPY RESISTANCE$163,224
P01 · FY2000 · CA
MOLECULAR SENSITIZATION OF P210BCR-ABL POSTIVIE CELLS TO THERAPY--CML$79,323
P01 · FY2000 · CA